160 related articles for article (PubMed ID: 29973197)
1. Nuclear Klf4 accumulation is associated with cetuximab drug-resistance and predicts poor prognosis of nasopharyngeal carcinoma.
Li X; Zhao Z; Yi S; Ma L; Li M; Liu M; Zhang Y; Liu G
J Transl Med; 2018 Jul; 16(1):183. PubMed ID: 29973197
[TBL] [Abstract][Full Text] [Related]
2. The Ras signaling pathway mediates cetuximab resistance in nasopharyngeal carcinoma.
Zuo Q; Shi M; Chen J; Liao W
Biomed Pharmacother; 2011 Jun; 65(3):168-74. PubMed ID: 21602020
[TBL] [Abstract][Full Text] [Related]
3. [Effects of silencing H-ras gene by RNA interference on cetuximab-sensitivity of cetuximab-resistant human nasopharyngeal carcinoma cells].
Zuo Q; Luo RC
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):574-8. PubMed ID: 22325215
[TBL] [Abstract][Full Text] [Related]
4. Predictive Value of [
Gu B; Liu S; Sun Y; Zhang J; Zhang Y; Xu X; Yuan H; Wang M; Zhang Y; Yang Z
Mol Imaging Biol; 2019 Jun; 21(3):538-548. PubMed ID: 30218389
[TBL] [Abstract][Full Text] [Related]
5. VPS33B interacts with NESG1 to modulate EGFR/PI3K/AKT/c-Myc/P53/miR-133a-3p signaling and induce 5-fluorouracil sensitivity in nasopharyngeal carcinoma.
Liang Z; Liu Z; Cheng C; Wang H; Deng X; Liu J; Liu C; Li Y; Fang W
Cell Death Dis; 2019 Apr; 10(4):305. PubMed ID: 30944308
[TBL] [Abstract][Full Text] [Related]
6. Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance.
Zuo Q; Shi M; Li L; Chen J; Luo R
Biomed Pharmacother; 2010 Oct; 64(8):550-8. PubMed ID: 20630698
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between the insulin-like growth factor 1 receptor signaling pathway and the resistance of nasopharyngeal carcinoma to cetuximab].
Zuo Q; Luo RC
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):575-9. PubMed ID: 21122407
[TBL] [Abstract][Full Text] [Related]
8. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Braig F; Voigtlaender M; Schieferdecker A; Busch CJ; Laban S; Grob T; Kriegs M; Knecht R; Bokemeyer C; Binder M
Oncotarget; 2016 Jul; 7(28):42988-42995. PubMed ID: 27119512
[TBL] [Abstract][Full Text] [Related]
9. Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling.
Hu WJ; Liu J; Zhong LK; Wang J
Biomed Pharmacother; 2018 Jun; 102():681-688. PubMed ID: 29604587
[TBL] [Abstract][Full Text] [Related]
10. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
11. Polo-Like Kinase 1 phosphorylates and stabilizes KLF4 to promote tumorigenesis in nasopharyngeal carcinoma.
Mai J; Zhong ZY; Guo GF; Chen XX; Xiang YQ; Li X; Zhang HL; Chen YH; Xu XL; Wu RY; Yu Y; Li ZL; Peng XD; Huang Y; Zhou LH; Feng GK; Guo X; Deng R; Zhu XF
Theranostics; 2019; 9(12):3541-3554. PubMed ID: 31281496
[No Abstract] [Full Text] [Related]
12. Loss of cytoplasmic KLF4 expression is correlated with the progression and poor prognosis of nasopharyngeal carcinoma.
Liu Z; Yang H; Luo W; Jiang Q; Mai C; Chen Y; Zhen Y; Yu X; Long X; Fang W
Histopathology; 2013 Sep; 63(3):362-70. PubMed ID: 23758499
[TBL] [Abstract][Full Text] [Related]
13. [Correlation between ras gene and the resistance of nasopharyngeal carcinoma to cetuximab].
Zuo Q; Luo RC
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun; 30(6):1415-7. PubMed ID: 20584693
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
Prenen H; De Schutter J; Jacobs B; De Roock W; Biesmans B; Claes B; Lambrechts D; Van Cutsem E; Tejpar S
Clin Cancer Res; 2009 May; 15(9):3184-8. PubMed ID: 19366826
[TBL] [Abstract][Full Text] [Related]
15. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
16. Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma.
Tai SK; Yang MH; Chang SY; Chang YC; Li WY; Tsai TL; Wang YF; Chu PY; Hsieh SL
Cancer Sci; 2011 Apr; 102(4):895-902. PubMed ID: 21219537
[TBL] [Abstract][Full Text] [Related]
17. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
[TBL] [Abstract][Full Text] [Related]
18. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
[TBL] [Abstract][Full Text] [Related]
19. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
[TBL] [Abstract][Full Text] [Related]
20. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
